Considering some patient challenges with taking daily oral therapy

Individuals featured have been compensated by ViiV Healthcare.

Real CABENUVA patients

Jorge

Wanted to move away from daily pills that could give away his HIV status

Age: 45 | Works as a mental health clinician

Treatment journey

Diagnosed in 2001, he struggled with accepting his HIV status and worried about daily adherence
While virologically suppressed, Jorge was worried about remembering to take his daily  HIV treatment
Switched to CABENUVA from BIKTARVY

Clinical profile

BMI: 23 kg/m²
Virologically suppressed
Highly engaged in care; consistently shows up for doctor appointments

Nonclinical considerations

Worried over remembering if he took his daily oral HIV medication
Does not want a daily reminder of his  HIV status

See preference data from BEYOND

MIRANDA

Wanted a treatment she didn’t have to worry about remembering to take daily

Age: 38 | Works as a prevention navigator in healthcare

Treatment journey

Diagnosed in 2000, she was worried about others knowing her HIV status
Discussed CABENUVA with her doctor
Switched to CABENUVA from BIKTARVY

Clinical profile

BMI: 31 kg/m²
Virologically suppressed on BIKTARVY
Highly engaged in care; consistently shows up for doctor appointments

Nonclinical considerations

Struggled with disclosing her HIV status to those around her and constantly worried about remembering to take her daily pill
Is in love and happily married; prides herself on managing her family's busy schedule

See challenge data from SOLAR

Miranda's switch to CABENUVA

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Miranda VO:

There were times where I forgot to take my HIV pills. You know, I’m living life and I get a little busy and you just forget. I’m human, I’m not perfect.

SUPER:

Miranda is a Patient Ambassador who has been compensated by ViiV Healthcare.

SUPER:

Video will resume in [icon counting down from 40 seconds]

VO:

For HIV-1 infection to replace a current, stable antiretroviral regimen in patients 12 years of age and older and weighing at least 35 kilograms with HIV-1 RNA less than 50 copies per mL, no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine. Do not use in patients with previous hypersensitivity to cabotegravir or rilpivirine or receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, more than a single dose of systemic dexamethasone, and St John’s wort.

Please see additional Safety Information and full Prescribing Information on this web page.

SUPER:

CABENUVA Important Product Information

For HIV-1 infection to replace a current, stable antiretroviral regimen in patients aged 12+ and ≥35 kg with HIV-1 RNA <50 copies/mL, no history of treatment failure and no known/suspected resistance to cabotegravir or rilpivirine. Do not use in patients with previous hypersensitivity to cabotegravir or rilpivirine or receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (>1 dose), St John’s wort.

Please see additional Safety Information and full Prescribing Information on this web page.

CABENUVA logo

SUPER:

Miranda’s Story

Interviewer VO:

Hey Miranda.

Miranda VO:

Hi!

Interviewer VO:

Can I steal you away for a little bit?

Miranda VO:

Yeah, one second.

Husband VO:

Sweetheart, I’ll go get a table.

Miranda VO:

Ok honey. Hey sis, what’s up?

Interviewer VO:

Thanks so much for taking time to chat. Why don’t you start by telling us a little bit about yourself?

Miranda VO:

My name is Miranda. I am 28 years old. No, I’m not though. (Laughter) I’m just playing, girl. I’m 38. And, um yeah, I have a loving family. I am married and I have two beautiful fur babies, Munchie and Moose.

Interviewer VO:

Adorable. Now I want to talk a little bit about your journey with HIV if that’s alright.

Miranda VO:

Yes, of course. I was diagnosed really young, at the age of 14. I came out to my family as a trans woman. And luckily, my mother took it very kindly. She was very accepting. But unfortunately, she was with a partner and that partner was very homophobic and he did not like it. I just wanted to find love and nurture and support, but I found it in all the wrong places. So I went on with my life, doing what I had to do to survive, which led to me becoming HIV positive.

Interviewer VO:

Thanks for sharing that. What was it like once you started daily oral therapy?

Miranda VO:

Stressful. (Laughs) There were times where I forgot to take my HIV pills. I’m living life and I get a little busy and you just forget. I’m human, I’m not perfect. The only thing that really stressed me out outside of the pills was knowing that they were around. And, you know, I like to host. But unfortunately, sometimes having a bottle in your medicine cabinet, you know, it just gives you away. People don’t understand how heavy a pill could be at times. I just kept carrying the burden of being HIV positive. So it made it really hard sometimes to be on oral medication for me.

Interviewer VO:

How did you find out about CABENUVA?

Miranda VO:

I work in the prevention sector for HIV, so I like to always understand medicine and what they’re for. And it just dawned on me, like you know, here I am advocating for other individuals living with HIV—what about me? I came to a conclusion that I am worth it. I am loved. And I am wanted. And I’m important. And here comes along an injectable option. And it works best for me!

SUPER:

This is Miranda’s unique experience.

Results may vary.

CABENUVA logo

Interviewer VO:

So what might you say to a doctor who’s a little reluctant to prescribe CABENUVA to their patients?

Miranda VO:

Well, first, it’s not about you, baby, it’s not. It’s about your patient. Not all of us are cut the same. I feel it’s important as a provider to take a step back and think about the patients that would benefit from CABENUVA and why they would benefit from CABENUVA. So allow your patients to have that option. Give them that freedom.

Interviewer VO:

So how do you feel now that you’ve made the switch to CABENUVA?

Miranda VO:

Switching to CABENUVA was absolutely worth it. You know, I’m able to focus on other more important things like my career, my love life, my family, and not having to be pulled back to popping open a bottle every night.

SUPER:

This is Miranda’s unique experience.

Results may vary.

CABENUVA logo

Interviewer VO:

Can you tell us a little bit about your life now with your husband? We’ll let you get back to him soon, I promise.

Miranda VO:

I remember when I met this man. And it was honestly sparks at first sight. So my husband is honestly my best friend. He’s the one that makes me laugh; he gives me a reason to get up in the morning. He makes life worth living.

SUPER:

With CABENUVA, shift Miranda’s focus to date night

SUPER:

The switch to CABENUVA can leave daily HIV treatment behind

SUPER:

Video will resume in [icon counting down from 23 seconds]

VO:

There have been reported hypersensitivity reactions; post-injection reactions; hepatotoxicity and depressive disorders. Common adverse reactions include injection site reactions; pyrexia; fatigue; headache; musculoskeletal pain; nausea; sleep disorders; dizziness and rash.

Please see additional Safety Information and full Prescribing Information on this web page.

SUPER:

CABENUVA Important Product Information (cont’d)

Reported: hypersensitivity reactions; post-injection reactions; hepatotoxicity; depressive disorders. Common adverse reactions: injection site reactions; pyrexia; fatigue; headache; musculoskeletal pain; nausea; sleep disorders; dizziness; rash.

Please see additional Safety Information and full Prescribing Information on this web page.

CABENUVA logo

SUPER:

Consider CABENUVA for your appropriate patients

SUPER:

IT STARTS WITH YOU

SUPER:

CABENUVA logo

Please see additional Safety Information and full Prescribing Information on this web page.

ViiV logo

For US Healthcare Professionals

Trademarks are owned by or licensed by ViiV Healthcare group of companies.

PMUS-CBRVID240017 June 2024 Produced in USA.

It starts with recognizing there are some patients who could benefit from a long-acting regimen

Patients entering SOLAR on BIKTARVY revealed challenges with taking continuing daily oral therapy at baseline

On Day 1, patients in SOLAR (N=670; mlTT-E) responded to 3 baseline questions about their previous experience on a daily oral therapy (exploratory endpoint).¹

Patient Ambassador Miranda on long-acting CABENUVA

47%

of patients in SOLAR reported experiencing at least one of the following challenges always or often*:

Worried about people unintentionally discovering their HIV status
Worried about forgetting to take their HIV medication
Felt that taking their HIV medication was an uncomfortable reminder of their HIV status

These results are descriptive in nature and should not be used to infer clinical significance.

Patients were asked each of the following questions: “How often are you worried people may unintentionally discover your HIV status because of your current HIV treatment?”; “How often are you worried about forgetting to take your HIV medication?”; and “How often is taking your HIV medication an uncomfortable reminder of your HIV status?” Patients who responded “always” or “often” to any of these questions were counted one time for the endpoints above.¹

SOLAR Study Design
SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY^1,2

A large phase 3b, open-label, noninferiority study of virologically suppressed* adults (≥18 years) with HIV-1
Efficacy analyses, baseline questionnaire, and preference calculation were based on the mITT-E (N=670) population. After consultation with a blinded external expert, 11 participants at a single study site were excluded from the ITT-E population due to critical findings related to significant and persistent noncompliance to protocol requirements

Safety analyses were based on ITT-E (N=681) population

Suppression defined as plasma HIV-1 RNA <50 copies/mL. A single prior INSTI-based regimen was allowed for reasons other than treatment failure.¹

39% (n=173) started with oral lead-in (OLI) and 61% (n=274) of patients in the CABENUVA arm started with injections (SWI) without OLI. OLI regimen consisted of 30-mg cabotegravir and 25-mg rilpivirine once daily given for 1 month; on last day of the OLI period, patients received 2 sets of initiation CABENUVA injections 1 month apart followed by every-2-month injections thereafter.¹

Month 12 (OLI and BIKTARVY) and Month 11 (SWI).¹

Each patient’s story offers a different perspective

Meet more CABENUVA patients

BMI=body mass index.

References:

Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
Data on file. ViiV Healthcare group of companies. Durham, NC.

PMUS-CBRWCNT240092

Considering some patient challenges with taking daily oral therapy

Real CABENUVA patients

Wanted to move away from daily pills that could give away his HIV status

Treatment journey

Clinical profile

Nonclinical considerations

Wanted a treatment she didn’t have to worry about remembering to take daily

Treatment journey

Clinical profile

Nonclinical considerations

Miranda's switch to CABENUVA

It starts with recognizing there are some patients who could benefit from a long-acting regimen

Patients entering SOLAR on BIKTARVY revealed challenges with taking continuing daily oral therapy at baseline

SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY1,2

SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY^1,2